Functional Precision Oncology, a new compass for cancer care | Apricot Bio
About this episode
The episode discusses functional precision oncology and its implications for cancer treatment with the founders of Apricot Bio.
In this special panel episode recorded in Zurich, the founders of Apricot Bio, Michael Zering (CEO), Lucas Pelkmans (Scientific Founder), and Independent Professor Andreas Wicki from the University of Zurich explore the new field of functional precision oncology—an approach that goes beyond genomics to test how living cancer cells actually respond to treatment. The conversation covers the limits of genetic diagnostics, the promise of ex vivo drug testing, AI-driven decision-making, and how smarter trial design could transform cancer care. The panel also dives into Switzerland’s biotech ecosystem, venture capital realities, and what it takes to bring high-risk, high-impact science from the lab to the clinic.
More episodes of Nucleate Podcast
- From Genomics to Deal-Making: How Science Becomes a Company | Laurence Reid, Biotech Entrepreneur
- Negotiating Intellectual Property, Staying Focused, and Making the Most of Mentors with Michal Preminger, Board Member at MassBio
- How Turbine Accelerates Drug Discovery with AI Simulation | Szabi Nagy, CEO and Co-Founder of Turbine
- The Science of Stem Cells and Social Impact: Inside Ovelle with Merrick Smela and Travis Potter
- Inside TechBio Investing | Claire Smith, Partner at Springtide VC
- The Art and Science of Drug Hunting | Christoph Lengauer, CSO & Co-Founder of Curie.bio
Explore listener stats, chart rankings, contacts and more on the Nucleate Podcast podcast page.